ロード中...
Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
Background: BAY 94-9027 is an extended half-life recombinant factor VIII (rFVIII) that prevents bleeding in persons with hemophilia A at twice-weekly, 5-day, and 7-day dosing intervals. In rare diseases such as hemophilia, where small populations preclude head-to-head comparisons in randomized contr...
保存先:
| 出版年: | J Blood Med |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6592019/ https://ncbi.nlm.nih.gov/pubmed/31417326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S206806 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|